| 07.21.21 | Sustained release specialist sold in $1.9B deal; Stevanato IPO raises $672M

Click here to subscribe to Fiercebiotech.com

3 years ago

Html
Text

Junshi commits $31M to mRNA joint venture To view this email as a web page, click here

Webinar: How lessons learned from the COVID pandemic will improve vaccine development in the future

Wednesday, August 11 | 11am ET / 8am PT

This Fierce webinar will include input from vaccine R&D professionals, including experts in clinical trial design, regulatory affairs and manufacturing. They will draw upon their own experiences in vaccine development to offer tips for incorporating elements of the successful COVID-19 vaccine rollout into future vaccine programs. Register Now.

Today's Rundown

Sustained release specialist sold in $1.9B private equity deal, teeing up push into U.S. market Stevanato IPO raises $672M to fund biologics, vaccine delivery Junshi commits $31M to pact with mRNA delivery specialist In a first, Micron starts testing microneedle vaccine in kids Pfizer antes up $345M to settle long-running EpiPen antitrust claims as Viatris case moves ahead

Featured Story

Sustained release specialist sold in $1.9B private equity deal, teeing up push into U.S. market

By Nick Paul Taylor

BC Partners has sold its majority stake in Pharmathen in a deal that values the sustained release drug delivery specialist at €1.6 billion ($1.9 billion). Private equity firm Partners Group has acquired the stake and outlined plans to accelerate the expansion of Pharmathen in the U.S.

Executive Summary: The Path to Self-Administration: Considerations for Moving from Pre-Filled Syringe to Auto-Injector

There are a number of important considerations for pharmaceutical companies that are considering a move to auto-injector devices. Learn how product characteristics, formulation, and patient needs impact device selection and manufacturing processes – and how experienced partners can help. Download Now.

Stevanato IPO raises $672M to fund biologics, vaccine delivery

By Nick Paul Taylor

Stevanato has listed its shares on the New York Stock Exchange. The IPO fell well short of Stevanato’s initial goal but still grossed $672 million to support investments in its biologics and vaccine delivery capabilities.

Junshi commits $31M to pact with mRNA delivery specialist

By Nick Paul Taylor

Junshi Biosciences is investing RMB 200 million ($31 million) in a joint venture with mRNA delivery specialist Immorna. The joint venture will start with investment from Junshi and mRNA intellectual property from Immorna.

In a first, Micron starts testing microneedle vaccine in kids

By Nick Paul Taylor

Micron Biomedical has begun trialing a microneedle-based measles-rubella vaccine in children. The Atlanta-based drug delivery specialist said the phase 1/2 study is the first time a microneedle vaccine has been tested in pediatric subjects.

Pfizer antes up $345M to settle long-running EpiPen antitrust claims as Viatris case moves ahead

By Fraiser Kansteiner

Pfizer and two of its subsidiaries have agreed to fork over $345 million to settle years of antitrust litigation surrounding their work on the pricey anaphylaxis injectable EpiPen. Less than a month ago, a federal court dismissed racketeering and some antitrust claims against another defendant in the case, Mylan, which is now Viatris.

eBook: Drug Design and the Patient Journey

Patient-focused drug design can be a key factor in real-world therapeutic outcomes and business success. But if successful treatments should be created with patients in mind, when is the optimal time to solicit this feedback? This eBook features insights from experts in the industry on patient-centric drug development challenges and strategies on advancing drug design and development effectively. Learn more.